Celiprolol - An Anti-hypertensive Drug

Overview

Given this mix of actions, Celiprolol might be better referred to as a selective adrenoceptor modulator. It possesses antihypertensive and antianginal qualities, and several nations worldwide have approved it for such usage. However, the treatment of vascular-type Ehlers-Danlos syndrome, a rare connective tissue illness characterized by fragile arterial structure and an elevated risk of life-threatening vascular consequences, is the proposed indication for this medication in the United States. Celiprolol may aid patients with vascular-type Ehlers-Danlos syndrome by lowering heart rate and pulsatile pressure, which may lessen the mechanical stress on collagen fibers within the artery wall. Due to the substantial advantage of Celiprolol in lowering arterial events in patients with this condition, the largest investigation of Celiprolol in vascular Ehlers-Danlos syndrome was prematurely stopped.

Which Class Does Celiprolol Belong To?

Some conditions, including arterial hypertension, systemic hypertension, angina, coronary heart disease, arrhythmias, hypertrophic cardiomyopathy, mitral valve prolapse, migraine, and glaucoma, are treated with adrenoceptor-blocking medications, also known as 1-adrenoceptor antagonists or beta-blockers.

The third-generation 1-adrenoceptor antagonist- Celiprolol

Drug Group:

(3-[3-acetyl-4-(3-t-butylamino-2-hydroxypropoxy)phenyl] -2,1-dimethylurea hydrochloride). It has a special pharmacological profile and partial 2 agonist action. It exhibits antihypertensive and antianginal activity similar to blockers but without the class's characteristic side effects, including bronchoconstriction, impairment of left ventricular function, and peripheral vasoconstriction. Its 2 agonist actions are probably to blame for this. Celiprolol may be better referred to as a selective adrenoceptor modulator (SAM) given this distinct mix of pharmacologic actions. Celiprolol may also be helpful for patients with concurrent lung and cardiovascular disease because of its capacity to excite 2-receptors, modify the vascular tone, and directly affect smooth muscle. The drug's distinctive features have stimulated research into the use of Celiprolol in a rare connective tissue disorder.

For Patients:

Why Is Celiprolol Prescribed?

Celiprolol is used for the treatment of hypertension or high blood pressure. Celiprolol can also aid patients with vascular-type Ehlers-Danlos syndrome by lowering heart rate and pulsatile pressure, which may lessen the mechanical stress on collagen fibers within the artery wall. Due to the substantial advantage of Celiprolol in lowering arterial events in patients with this condition, the largest investigation of Celiprolol in vascular Ehlers-Danlos syndrome was prematurely stopped.

What to Do Before Taking Celiprolol?

Some medical problems preclude using some medications; at other times, medication can only be administered with special precautions. For the following reasons, the doctor must be aware before start using Celiprolol:

• If one is nursing a baby or pregnant.

• If one suffers from asthma or another breathing condition.

• If one's kidney or liver function is not as it should be or if one has other health issues.

• If one has weak circulation or low blood pressure.

• The condition of diabetes (diabetes mellitus).

• If one suffers from psoriasis, a skin condition.

• If one suffers from myasthenia gravis, a disease that causes muscle weakness.

• If one has been diagnosed with a heart block or a slow heartbeat (a slow and irregular heartbeat).

• If one has been diagnosed with Prinzmetal's angina (variant angina, angina inversa, and vasospastic angina are other names for Prinzmetal's angina. Chest pain that results from insufficient blood supply to the heart muscle—typically brought on by coronary artery disease—is referred to as angina), which is chest pain brought on by heart blood vessel spasms.

• If one takes additional medications, this covers prescription-free drugs and over-the-counter, herbal, and complementary medications.

• If one has ever experienced a severe allergic reaction, whether to a medication or something else.

How Should Celiprolol Be Taken?

Read the printed information sheet inside the package provided by the manufacturer before users begin the therapy. In addition to providing customers with a comprehensive list of possible adverse effects, it will provide the patient with further details about Celiprolol.

Take Celiprolol as directed by a physician. Tablets come in 200 mg (milligrams) and 400 mg concentrations. Although the doctor may eventually increase the dosage to a 400 mg tablet, it is typical to begin by taking one 200 mg tablet daily. One should take the tablet first thing in the morning. This implies that one should take the tablet two hours after breakfast or at least 30 minutes before a meal. Drink some water and swallow the tablet.

If anyone misses a dose, they should take it as soon as they remember (without food, if possible). If users do not realize the missing dose until the next day, leave it out. Do not take two doses at once to make up for a missed dose.

How to Maximize One’s Treatment?

Attempt to attend all of the scheduled doctor's appointments. This will enable the doctor to monitor the development.

• The doctor will probably advise the patient to follow a healthy diet, abstain from smoking, and exercise regularly. If so, one must heed the counsel offered to them.

• If anyone consumes alcohol, see the physician before using Celiprolol. Alcohol may not be advised for patients since it will increase the blood pressure-lowering effects of Celiprolol, which will cause one to feel lightheaded.

• When purchasing any medications, ensure a chemist has approved them with Celiprolol (including some anti-inflammatory painkillers and cold or flu remedies).

• It is crucial to inform the doctor if you are taking a beta-blocker. This is especially crucial if you are going to get anesthesia.

• Celiprolol helps prevent the symptoms of low blood sugar if one has diabetes. In this case, the doctor will provide them with advice.

Celiprolol therapy is typically prolonged.

If the doctor does not tell them to stop taking the pills, keep taking them. If it becomes necessary to reduce the dose, the doctor may request that one do so gradually because stopping therapy abruptly can have adverse effects on some patients.

What Are the Side Effects of Celiprolol?

• If you are feeling faint, drowsy, exhausted, or light-headed, it might be helpful to stand up and move more gently.

• If anyone starts to feel lightheaded, lie down to avoid passing out, then sit for a while before standing. This frequently gets better after the first week or two, but if it persists, consult the doctor. If impacted, refrain from operating machinery or driving until they feel better.

• Headache. Ask your chemist for a good painkiller recommendation and drink plenty of water. If the headaches persist, describe them to the doctor.

• Nausea or vomiting, as well as stomach discomfort.

• Eat basic foods only, and get lots of water.

• Cool hands and feet, restless nights, breathing issues, a slow heartbeat, impotence, diminished sexual desire, and dry skin.

• If you have any other symptoms that you believe may be related to the medication, speak with the doctor or chemist for more guidance.

How Is Celiprolol Stored?

• Keep any medications out of children's sight and reach.

• Keep away from direct heat and light in a cool, dry area.

For Doctor:

Indications:

Celiprolol is indicated for the treatment of hypertension.

Pharmacology:

Mechanism of Action:

A partial beta-2 agonist with vasoactive beta-1 selective adrenoceptor antagonist action, Celiprolol. Its mild vasodilating characteristics are believed to be caused by the beta-2 agonist action. In hypertensive patients, it decreases blood pressure at rest and during exercise. Celiprolol reduces chronotropic and inotropic reactions to sympathetic stimulation under stressful circumstances, such as during exercise. Nonetheless, there is only a slight reduction in heart function at rest.

Pharmacokinetic Properties of Celiprolol:

The therapeutic effects of 1-adrenoceptor antagonists are comparable overall. However, they differ in terms of pharmacokinetics. This is explained by the fact that each of these compounds has a unique aromatic ring structure, which causes variations in each drug's absorption, metabolism, first-pass hepatic metabolism, lipid solubility, protein binding, and renal clearance. The structure of the side chain's asymmetric -carbon specifically controls whether an action is one of activation or blockage. Celiprolol is closely related to Acebutolol in its aromatic ring structure (benzene), comparable to other 1-adrenoceptor antagonists.

Absorption:

Antagonizers of the 1-adrenoceptor for absorption might be hydrophilic or lipophilic. Celiprolol is a hydrophilic substance that is easily soluble in water. Except for Atenolol, most 1-adrenoceptor antagonists are absorbed in the small intestine. With oral Celiprolol dosages of 100 to 600 mg, the mean peak plasma concentrations range from 300 to 3000 grams per liter. Celiprolol has a dose-dependent bioavailability of 30 percent at 100 mg and 70 percent over 300 to 400 mg. Meals may reduce their bioavailability, although the impact on long-term therapy is not clinically significant. It has been demonstrated that the organic anion-transporting polypeptide 1A2 (OATP1A2) inhibitors of grapefruit and orange juice significantly reduce the oral absorption of Celiprolol. Studies have indicated that the effects of Celiprolol on blood pressure and heart rate are unaffected, even though the therapeutic importance of this interaction has yet to be extensively evaluated.

Distribution:

The circulation quickly distributes 1-adrenoceptor antagonists to various tissues. Celiprolol's distribution in both people and animals has been investigated. After absorption, it was discovered that Celiprolol is a water-soluble chemical broadly dispersed in all tissues except the brain. This is probably because of its hydrophilic characteristics. According to in vitro research, Propranolol, Timolol, and Labetalol, which have comparable blocker activity, have about 25 percent plasma protein binding, and the rate of diffusion across the human placenta is 3 to 4 times lower. It is unknown whether Celiprolol carries a lower risk of fetal problems as a result.

Metabolism

Celiprolol undergoes extremely little metabolization; only a small portion of the dosage is eliminated. Like other 1-adrenoceptor antagonists, it exhibits first-pass metabolism. However, its concentration is significantly lowered before it enters systemic circulation. A small trial in healthy volunteers showed that prolonged dosing over seven days did not result in drug buildup.

Excretion

Drugs targeting the 1-adrenoceptor are categorized into two groups based on their pharmacokinetic characteristics: cleared through hepatic metabolism and eliminated (unchanged) through the kidney. The pharmacokinetics of celiprolol have been investigated in animals and people with primary hypertension and chronic stable angina pectoris. According to research, Celiprolol has a half-life of around four to five hours, is only barely digested, and is eliminated unaltered in the urine and feces.

Pharmacodynamic Properties of Celiprolol

The third-generation adrenoceptor antagonist, Celiprolol, was created with selective 1-antagonist, partial 2-agonist, and mild 2-antagonist activities. The 2 antagonist's ability to counteract the effects of the 2 agonist Clonidine is minimal and ineffectual. Therefore, Celiprolol's activities as a 2 agonist are thought to make up a small portion of its overall pharmacologic effect. Its inhibition of 1-adrenoreceptors lessens the heart's sympathetic activation during physiological stress. Moreover, the sinoatrial node experiences a decrease in heart rate (negative chronotropic effect) and a decrease in cardiac contractility (negative inotropic effect) due to Celiprolol's blockage of 1-adrenoreceptors.

A 2013 research of swine coronary arteries showed that Celiprolol exerts 3-adrenoceptor agonistic activity with subsequent vasorelaxation, supporting the notion that Celiprolol enhances vasodilation through 2 agonists and may also operate on 3 receptors. Moreover, Celiprolol's increase in nitric oxide release has the potential to cause coronary vasodilation. Celiprolol may be superior to other --adrenergic antagonists because of its activity profile, including minimal lipid effects, minor cardiac conduction effects, and broncho-sparing qualities.

Cardiovascular Effects:

Research supports the claim that Celiprolol enhances blood flow without impairing heart function by lowering artery resistance. A 400 mg oral dose in healthy people decreased standing diastolic blood pressure by around 10 percent while not affecting systolic blood pressure. Celiprolol did not lower resting cardiac output in patients with hypertension, but it did decrease the beneficial chronotropic effects of sympathetic arousal and lower resting total peripheral resistance. In vivo, animal investigations on Celiprolol's impact on cardiac conduction showed that, despite activating cardiac 2-adrenoceptors, the drug did not speed up the ventricular rate during electrically induced atrial fibrillation. Celiprolol also lacked any membrane-stabilizing or local anesthetic properties. A short investigation of patients with stable atrial fibrillation found that Celiprolol treatment raised the normalized maximal rate of left ventricular pressure reduction immediately after systole (dP/dtip) by 24 percent and decreased the left ventricular relaxation time constant by 20 percent.

In addition, Vyssoulis et al. reported that celiprolol reduces left ventricular size as measured by end-systolic and diastolic diameters, interventricular septal thickness, and posterior wall thickness at end diastole and end systole in individuals with left ventricular hypertrophy.

Small studies using Celiprolol in patients with heart failure have seen variable outcomes. Three months of Celiprolol medication in a study of 16 patients with reduced left ventricular ejection fraction (LVEF) improved LVEF. They had hemodynamic effects in patients with nonischemic cardiomyopathy, whereas the effects on patients with ischemic cardiomyopathy were equivocal.

Celiprolol and the placebo performed similarly in the key end goal of change in functional status (measured by the Goldman score) after a year of treatment, according to larger research involving 132 patients with decreased LVEF. The heart rate was decreased more, and the DiBianco heart failure score, a composite of exertional and decubitus dyspnea, asthenia, and leg edema, was decreased more with Celiprolol than with placebo. Still, other efficacy measures did not differ significantly from any other (LVEF, end-diastolic diameter, fractional shortening, and exercise duration). Overall, these short studies suggested that Celiprolol was safe in this population even though they did not consistently demonstrate the drug's effectiveness in treating heart failure.

Respiratory Effects:

Studies have been done on how Celiprolol affects patients with and without asthma in terms of their ability to breathe. Although Celiprolol (200 or 400 mg) given as a single dose did not affect the respiratory function of asthma patients, Celiprolol has been associated with bronchospasm and asthma in non-asthmatic individuals with ischemic heart disease and hypertension. Hence, monitoring for respiratory symptoms is still advised when Celiprolol is used in patients, whether they have asthma or not.

Metabolism Effects:

Like -adrenoceptor antagonists, Celiprolol has no negative effects on lipid and lipoprotein profiles, but unlike many other 1-adrenoceptor antagonists, it may have minor positive effects. Celiprolol 200 mg once a day decreased low-density lipoprotein cholesterol (LDL-C) levels in hyperlipidemic patients (baseline LDL-C >160 mg/dL) by 16.9 percent and total cholesterol by 12.8 percent in a trial of 100 patients with hypertension. Those having LDL-C levels below 160 mg/dL at baseline showed no discernible changes.

Celiprolol 100 to 400 mg once a day did not cause any appreciable changes in glomerular filtration rate, renal plasma blood flow, plasma renin activity, filtration fraction, serum creatinine, aldosterone, or urine enzymes in a small placebo-controlled, crossover research.

Some of the Common Drug Interactions:

1. Abaloparatide: Abaloparatide may enhance Celiprolol's hypotensive effects.

2. Abatacept: When taken with Abatacept, Celiprolol's metabolism can be accelerated.

3. Abiraterone: Combining Celiprolol and Abiraterone can slow down its metabolism.

4. Acarbose: Acarbose can have a greater therapeutic effect when used with Celiprolol.

5. Acebutolol: The arrhythmogenic effects of Celiprolol may be enhanced by Acebutolol.

6. Aceclofenac: Aceclofenac may lessen Celiprolol's antihypertensive effects.

7. Acemetacin: Acemetacin may lessen Celiprolol's antihypertensive effects.

8. Acetaminophen: Combining Celiprolol and Acetaminophen may slow down its metabolism.

9. Acetohexamide: When administered with Celiprolol, Acetohexamide can have a more significant therapeutic effect.

10. Acetophenazine: When coupled with Acetophenazine, Celiprolol's serum levels can rise.

11. Acetylcholine: When Celiprolol and Acetylcholine are combined, the likelihood or severity of side effects may rise.

12. Acetyldigitoxin: Acetyldigitoxin may enhance Celiprolol's arrhythmogenic effects.

13. Acid acetylsalicylic: Acetylsalicylic acid may reduce Celiprolol's antihypertensive effects.

14. Acrivastine: Combining Celiprolol and Acrivastine can make QTc prolongation more likely or severe.

15. Adagrasib: Combining Celiprolol and Adagrasib may slow down its metabolism.

16. Adalimumab: When taken with Adalimumab, Celiprolol's metabolism may be sped up.

17. Adenosine: Celiprolol's arrhythmogenic actions may be enhanced by adenosine.

Adverse Effects:

There was no difference in adverse events between Celiprolol and placebo, according to a compilation of data from clinical trials including individuals with primary hypertension, /or angina pectoris. Further research has revealed that Celiprolol has a better tolerability profile than propranolol and atenolol, as it does not cause clinically significant bradycardia and causes less fatigue, dizziness, and exhaustion. Celiprolol should not be used in patients with cardiogenic shock, decompensated heart failure, sick sinus syndrome, second or third-degree heart block, or severe bradycardia; however, just like other -blockers.

Celiprolol may relax bronchial smooth muscle, which makes it theoretically safe for usage in individuals with pulmonary illness, in contrast to other blockers. According to numerous studies, Celiprolol does not significantly impair respiratory performance in those with asthma or chronic obstructive pulmonary disease. Nonetheless, there have been reports of asthma attacks and bronchospasms in Celiprolol-treated individuals, as well as one case of hypersensitivity pneumonitis that returned after the medicine was taken again. As a result, monitoring for respiratory symptoms is still advised, even in those who do not have lung illness or those who are taking Celiprolol for lung disease.

Conclusion

One class for all -adrenoceptor antagonists. The authors talked about a three-state receptor activation model related to ligand-biased signaling. Reviewing clinical data that showed that not all -adrenoceptor antagonists were successful in treating congestive heart failure best illustrated this. This supports the notion that categorizing -adrenoceptor antagonists should be based on several variables, including affinity, 1-selectivity, partial agonist activity, and physicochemical characteristics.

Based on Celiprolol's distinct pharmacological profile, which includes a 1 adrenergic antagonist with partial 2 agonist activity, reported 3-agonism, mild 2-antagonism, lack of membrane-stabilizing or local anesthetic activity, vasodilator properties, and the rarity of typical side effects of the -adrenergic antagonist class.